Fig. 2
From: Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
Progression-free survival time. a:Progression-free survival time of patients treated with pemetrexed-based therapy The “HER2” group were compared with the “EGFR”, “KRAS” and “ALK/ROS1” groups. b: Progression-free survival time of patients with HER2-mutant lung adenocarcinomas treated with pemetrexed-based therapy. The A775_G776insYVMA group were compared with the other variants group (n=7, 3with P780_Y781insGSP, 2with G776>IC, 1with G776>LC, and 1with G776C)